Evidence map›Paper›PMID 24710039›Full record

ArticleGenes2010

Next generation sequencing: advances in characterizing the methylome.

Kristen H Taylor, Huidong Shi, Charles W Caldwell

Abstract read
In one paragraph

Article in Genes, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. A Versatile Assay for Detection of Aberrant DNA Methylation in Bladder Cancer.Methods in molecular biology (Clifton, N.J.) · 2018
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Kristen H TaylorUniversity of Missouri-Columbia School of Medicine, Ellis Fischel Cancer Center, Columbia, MO 65212, USA. taylorkh@health.missouri.edu.
Huidong ShiMedical College of Georgia, Augusta, GA 30912, USA. hshi@mcg.edu.
Charles W CaldwellUniversity of Missouri-Columbia School of Medicine, Ellis Fischel Cancer Center, Columbia, MO 65212, USA. caldwellc@health.missouri.edu.

Funding

Genome-scale anaylsis of DNA methylation in CpG Islands with bisulfite sequencingR01DA025779 · NIDA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI SHI, HUIDONG, ZHANG, KUN · 2008 to 2011
$2.3M
Epigenetic Signature of Non-Hodgkin's LymphomasR33CA097880 · NCI · UNIVERSITY OF MISSOURI-COLUMBIA · PI CALDWELL, CHARLES W · 2004 to 2007
$1.4M
DNA Methylation in Non-Hodgkin's LymphomasR01CA100055 · NCI · UNIVERSITY OF MISSOURI-COLUMBIA · PI CALDWELL, CHARLES W · 2003 to 2006
$1.0M
Towards defining the functional methylome in acute lymphoblastic leukemiaR00CA132784 · NCI · UNIVERSITY OF MISSOURI-COLUMBIA · PI TAYLOR, KRISTEN H · 2011 to 2013
$694k
Epigenetic Targeting in Non-Hodgkin's LymphomaR21CA123018 · NCI · UNIVERSITY OF MISSOURI-COLUMBIA · PI SHI, HUIDONG · 2006 to 2007
$365k
Toward Defining the Functional Methylome in Acute Lymphoblastic LeukemiaK99CA132784 · NCI · UNIVERSITY OF MISSOURI-COLUMBIA · PI TAYLOR, KRISTEN H · 2009 to 2010
$229k
Epigenetic Signature of Non-Hodgkin's LymphomasR21CA097880 · NCI · UNIVERSITY OF MISSOURI-COLUMBIA · PI CALDWELL, CHARLES W · 2003 to 2003
$143k
NCI NIH HHS K99 CA132784NCI NIH HHS R00 CA132784NCI NIH HHS R01 CA100055NCI NIH HHS R21 CA097880NCI NIH HHS R21 CA123018NCI NIH HHS R33 CA097880NIDA NIH HHS R01 DA025779
6 · The paper itself

Abstract

Epigenetic modifications play an important role in lymphoid malignancies. This has been evidenced by the large body of work published using microarray technologies to generate methylation profiles for numerous types and subtypes of lymphoma and leukemia. These studies have shown the importance of defining the epigenome so that we can better understand the biology of lymphoma. Recent advances in DNA sequencing technology have transformed the landscape of epigenomic analysis as we now have the ability to characterize the genome-wide distribution of chromatin modifications and DNA methylation using next-generation sequencing. To take full advantage of the throughput of next-generation sequencing, there are many methodologies that have been developed and many more that are currently being developed. Choosing the appropriate methodology is fundamental to the outcome of next-generation sequencing studies. In this review, published technologies and methodologies applicable to studying the methylome are presented. In addition, progress towards defining the methylome in lymphoma is discussed and prospective directions that have been made possible as a result of next-generation sequencing technology. Finally, methodologies are introduced that have not yet been published but that are being explored in the pursuit of defining the lymphoma methylome.

Identifiers

PMID24710039
PMCPMC3954092

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.